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Abstract
Background: There is great potential for using transgenic technology to improve the quality of cow milk and to produce
biopharmaceuticals within the mammary gland. Lysozyme, a bactericidal protein that protects human infants from
microbial infections, is highly expressed in human milk but is found in only trace amounts in cow milk.
Methodology/Principal Findings: We have produced 17 healthy cloned cattle expressing recombinant human lysozyme
using somatic cell nuclear transfer. In this study, we just focus on four transgenic cattle which were natural lactation. The
expression level of the recombinant lysozyme was up to 25.96 mg/L, as measured by radioimmunoassay. Purified
recombinant human lysozyme showed the same physicochemical properties, such as molecular mass and bacterial lysis, as
its natural counterpart. Moreover, both recombinant and natural lysozyme had similar conditions for reactivity as well as for
pH and temperature stability during in vitro simulations. The gross composition of transgenic and non-transgenic milk,
including levels of lactose, total protein, total fat, and total solids were not found significant differences.
Conclusions/Significance: Thus, our study not only describes transgenic cattle whose milk offers the similar nutritional
benefits as human milk but also reports techniques that could be further refined for production of active human lysozyme
on a large scale.
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Introduction
Lysozyme, also known as muramidase, was first described by
Alexander Fleming [1]. This enzyme is a type of glycanhydrolase,
which hydrolyzes the b-1,4-linkages between N-acetylmuramic acid
and N-acetyl-D-glucosamine residues in the peptidoglycan of
bacterial cell walls. Lysozyme has been found in variety of species [2].
Human lysozyme (HLZ) is a C-type lysozyme that consists of a
single polypeptide of 130 amino acid residues (molecular mass
<14.7 kDa) [3]. It is a positively charged protein with high pI
(<11) under normal human physiological conditions [4]. HLZ is
widely distributed in human tissues and body fluids (tears, saliva,
milk) [5,6] and it plays important roles as a non-specific immune
factor and anti-inflammatory factor [7]. Furthermore, some
reports have shown that HLZ has anti-fungal and anti-viral
activities [8,9]. Moreover, changes in the HLZ concentration in
serum or urine is used as a diagnostic marker for certain diseases
[10]. Also, HLZ is under study as a potentially useful material for
use in food products, cosmetics (as a preservative), medicine feed,
baby formula, and so on [11–13].
The benefits of lysozyme present in breast milk to improve
immunity and prevent infection in infants, are gaining attention. It
increases the levels of beneficial intestinal microflora and
strengthens disease resistance in infants. These effects are believed
to occur through the lysis of certain potentially damaging Gram-
positive bacteria and a few Gram-negative bacteria in the
gastrointestinal tract of breast-fed babies [14,15]. The content of
lysozyme in human milk ranges from 3 to 3000 mg/ml, and the
typical concentration is about 200–400 mg/ml [16,17]; however,
only trace amounts are found in the breast milk of ruminants.
Bovine milk typically contains only 0.05–0.22 mg/ml of lysozyme
[16,18]. In addition, its activity is 1/10 of lysozyme from human
breast milk [16,19]. Despite the benefits that HLZ provides to
breast-fed infants, mothers do not always desire to lactate and
sometimes situations prevent lactation; therefore, the development
of alternate sources of HLZ would be beneficial to infant health.
The development of genetic engineering has enabled the
expression of HLZ in microorganisms [20], eukaryotic cells [21]
and plants [22]. In recent years, the mammary gland has been
considered as a potential bioreactor for the expression of
recombinant proteins [23], which appears to be capable of
appropriate post-translational modifications of recombinant pro-
teins [24]. After synthesis in mammary epithelial cells, recombi-
nant proteins are immediately secreted into milk through the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17593signal peptide design to the vector; this makes it easier to purify
recombinant proteins using relatively simple chromatographic
methods. Still, the milk of dairy cows is easily obtained and
continuously available. So, using of the mammary gland
bioreactor system of dairy cows provides not only a good new
way to produce rHLZ but also a way to transfer the benefits of
human milk to cow milk. Moreover, expression of rHLZ might
help dairy animals resist the growth of bacteria which cause
mastitis [25]. Maga et al. expressed rHLZ in the mammary gland
of transgenic mice [26]. Shortly thereafter, a line of transgenic
goats that expressed rHLZ was generated [27].
We previously produced transgenic mice that expressed rHLZ
[28]. In the present study, we produced cloned transgenic cattle
that expressed rHLZ in breast milk, and we tested the
physicochemical characteristics of the rHLZ that was expressed.
We also optimized a method for purifying rHLZ from breast milk
of transgenic cattle for potential large-scale production in the
future.
Results
Generation of cloned transgenic cattle that express rHLZ
The pBC2-HLY-NEOR transgene vector contains the HLZ
coding region, a bovine b-casein signal peptide DNA sequence,
and one selection marker, the neomycin resistance gene (Neor)
were used (Figure 1A). After somatic cell nuclear transfer (SCNT),
312 blastocysts were transferred into recipient cattle. Thirty-seven
calves were born at full term (2 from cell strain of fetal genital
ridge, FG; 11 from cell strain of fetal oviduct epithelial cells, FOV;
23 from cell strain of fetal oviduct epithelial cells 19, FOV-19; and
1 from cell strain of bovine fetal fibroblasts b1, BWFF-b1). Seven
calves died within a few hours after birth, and six calves died
within 6 months after birth. Twenty-four calves survived and were
healthy after weaning; these calves were from two cell types,
genital ridge cells (2 calves) and oviduct epithelial cells (22 calves).
After the PCR and Western blot detection, we have created 17
healthy cloned transgenic cattle that expressed rHLZ, but only 4
transgenic cattle, 0503, 0504, 1241, and 1242 were lactating
normally in the research time. Thus the data from subsequent
experiments to be report just focus on those four transgenic cattle.
By PCR analysis, HLZ was integrated into the genome of the
four transgenic cattle (Figure 1B). Southern blot analysis revealed
that the cattle derived from different cell strains (0503 and 0504
from FOV, 1241 and 1242 from FG) carried different copies of
HLZ (The copy number of 0503, 0504, 1241 and 1242 are 2, 7, 1,
1 respectively) in their genomes (Figure 1C). RNA expression of
HLZ was detected in the mammary epithelial cells from each
transgenic cow (Figure 1D). Milk from the four transgenic cattle
that were lactating normally was collected to confirm the
expression of the rHLZ protein. The results showed that all four
cattle expressed rHLZ protein (Figure 1E). Radioimmunoassay
was used to quantify rHLZ levels. The concentration of rHLZ was
17.6967.56 mg/ml for cow 1242, 13.2560.46 mg/ml for cow
1241, 18.9963.78 mg/ml for cow 0503, and 25.9662.53 mg/ml
for cow 0504. We also detected changes in the concentration of
rHLZ in the milk of naturally lactating cow 1242 over the first
month of lactation. The amount of rHLZ declined in the first
month of lactation but then appeared to stabilize (Figure S1).
Compositional analysis of the milk derived from
transgenic cattle
Milk samples from transgenic and non-transgenic cattle were
collected each month for 6 months during their natural lactation
period. There were no significant differences on the amount of fat,
protein, lactose, and milk solids in the milk of transgenic and non
transgenic cattle (P=0.546, 0.678, 0.672, 0.837, respectively), as
shown in Table 1.
Purification of rHLZ from transgenic milk
A two-step purification method was developed to purify rHLZ.
The main factors influencing rHLZ extraction are pH value and
ionic strength of the buffer [29]. We conducted a series of
preliminary experiments to find the best conditions for purification
of rHLZ. The results of those experiments showed that the optimal
condition was with 20 mM sodium phosphate buffer at a pH of 8.5.
As this condition, the elution profile showed the best elution peak
width and peak intensity. After removing fat and casein from the
milk, a cation exchange column was used during the first step of the
purification method to remove most of the whey protein. Most
proteins appeared in the elution fluid. rHLZ was eluted with 0.3 M
sodium chloride in 20 mM sodium phosphate buffer, pH 8.5
(Figure 2A). SDS-PAGE and western blot analysis determined that
the purified protein in peak P2 was rHLZ (Figure 2A, B and C). In
order to achieve higher purity (.95%), the fractions containing
rHLZ were further purified in the second step of the purification
process bygel-filtration chromatographyin0.15 M sodiumchloride
with 20 mM sodium phosphate buffer, pH 7.2. The high-purity
rHLZ in fraction P2 was detected by SDS-PAGE, silver-stained
PAGE (15% gel) and western blot (Figure 2D, E, F and G). The
purity of the final concentrated product exceeded 95% when
analyzed using Quantity One software (Figure 2G). As a control, we
also used the same purification procedures to successfully purify
HLZ from human milk (data not shown). The highly pure rHLZ
was used in subsequent experiments, with commercial HLZ used as
a positive control.
Comparison of the properties of rHLZ with that of other
lysozymes
Peptide mass fingerprinting, molecular mass, and N-
terminal analysis. The bands corresponding to purified rHLZ
and commercial HLZ were removed from the gel for peptide mass
fingerprinting (PMF). The results showed that purified rHLZ and
commercial HLZ have the same fingerprinting patterns, and rHLZ
was assigned to HLZ (number of matched peptides and score not
shown). SDS-PAGE analysis of purified rHLZ indicated that its
apparent mass was similar to that of commercial HLZ (Figure 2G).
To improve the accuracy of the mass measurements, we compared
the two mass spectra generated by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS).
The slight molecular mass differences (about 5 Da) between rHLZ
and commercial HLZ was detected (Table 2). N-terminal amino
acid sequence analysis further confirmed that purified rHLZ was
identical to HLZ from breast milk (KVFERCELARTLKRL,
GenBank accession no. CAA32175.1; Table 2). rHLZ differed
from bovine lysozyme at three amino acids in the N-terminal
sequence (K(K)F(Q)RCELARTLK(K)L, GenBank accession
no. AAT92538.1).
Lysozyme activity assay. We used two methods to analyze
the bactericidal activity of purified rHLZ, and we compared the
activity of rHLZ with that of commercial HLZ and commercial
hen egg white lysozyme.
In an agar diffusion test, the inhibition zones for 2-mg samples
were clearly visible after an incubation of 24 h. There was no
inhibition zones on filter paper filled with distilled water (negative
control). rHLZ showed strong lytic activity, similar to that of
commercial HLZ. Commercial hen egg white lysozyme had about
one-third of the lytic activity of rHLZ (Figure 3). To test the
influence of salt concentration on lysozyme activity, we compared
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ddH2O, termed rHLZ-1, with that of purified rHLZ that had not
been desalinated. The lytic activity of rHLZ-1 was lower than that
of rHLZ (Figure 3 and Table 3).
The same samples also were examined by the turbidimetric
method. The data showed that the lytic activity of rHLZ against
Micrococcus lysodeikticus was similar to that of purified HLZ and two
to three times higher than that of commercial hen egg white
lysozyme (Table 3). These results were similar to those from the
agar diffusion test.
Optimal temperature and thermostability. From the
data shown (Table 4), there were no significant differences
between the activities of HLZ and rHLZ in different
temperature conditions we set (P.0.05). In addition, the average
activity of 40uC was higher than that of 25uC (P=0.048),60uC
Figure 1. Expression of rHLZ. (A) Schematic drawing of pBC2-HLY-NEOR. The lower bars represent the PCR products used for identification of the
transgene. Globin insulator (26), two copies of chicken b-globin insulator; casein E1–E2, goat b-casein exon 1, intron 1, and part of exon 2 (before
initial codon); sigbCN+hly, bovine b-casein signal peptide DNA sequence and HLZ coding region; casein E7–E9, goat b-casein exon 7, intron 7, exon 8,
intron 8, and exon 9; casein 39 genomic DNA, goat b-casein 39 genomic region. (B) PCR analysis of transgenic cattle. M represents DNA ladder; B
represents blank control; N represents non-transgenic cattle and P represents positive control form constructed vector. (C) Southern blot analysiso f
transgenic cattle. Genomic DNA (20 mg per lane) was isolated from ear biopsies of cattle and digested with EcoRI. The bands were hybridized to a
565 bp specific probe that is complementary to a fragment of the HLZ gene. lanes 1, 2, and 5 represent positive controls with 1, 2, and 5 copies,
respectively. N, genomic DNA from a non-transgenic cattle; 0503, 0504, 1241, and 1242 represent genomic DNA from transgenic cattle. (D) RT-PCR
analysis of transgenic cattle. Total RNA was isolated from mammary epithelial cells. The 322-bp fragments represent the RT-PCR products of rHLZ, and
the 121-bp fragments represent the RT-PCR products of GAPDH. M, DNA ladder; B, blank; C, negative control; N, non-transgenic cattle. (E) Western
blot analysis of transgenic cattle. Samples of skim milk (1 ml each) were separated by SDS-PAGE and hybridized with anti-HLZ. HLZ, commercial HLZ
(positive control); N, non-transgenic milk; HM, skim human milk; the other lanes, milk from transgenic cattle.
doi:10.1371/journal.pone.0017593.g001
Table 1. Raw components of transgenic milk compared with
conventional milk.
Transgenic (n=4) Non transgenic (n=4)
Fat (g/100 ml) 4.8260.67 4.560.74
Protein (g/100 ml) 3.3260.34 3.4160.23
Lactose (g/100 ml) 4.8160.08 4.8960.32
Solids (g/100 ml) 13.6561.05 13.560.98
No significant differences were detected between transgenic group and non
transgenic group (P.0.05).
doi:10.1371/journal.pone.0017593.t001
Recombinant Human Lysozyme
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17593(P=0.006) and 80uC (P=0.002). And, the different of 25uC and
60uC was not significant (P=0.247). The relative activity of rHLZ
and HLZ were also compared under three different heating
conditions (60uC, 80uC, and 100uC) to reveal their super
thermostablilty (Figure 4). rHLZ maintained nearly 95% of its
activity at 25uC after a 45-min incubation at 60uC. The relative
lytic activity of rHLZ and HLZ decreased when incubated at 80uC
or 100uC within 40 min. After 10-min incubation at 100uC, the
lytic activity was nearly 50% lower than that at 25uC. And lytic
activity was very low after a 30-min treatment. The
thermostability profiles of rHLZ and HLZ were similar (Figure 4).
Optimal pH and pH stability. The lytic activity of rHLZ
and commercial HLZ was tested using three buffers with different
salt concentration at different pH values (pH 2–11). The optimal
pH of rHLZ varied with salt concentration of the buffer (Figure 5).
The highest activity of the purified rHLZ was at pH 7 when the
salt concentration was 0.05 M of the buffer. The highest activity of
rHLZ was at pH 6 when the salt concentration of the buffer was
0.1 M. When using a buffer with a salt concentration of 0.05 M,
rHLZ showed lytic activity across a broader range of pH values
(pH 5–9) than salt concentration of buffer was 0.1 M. The lytic
activity of rHLZ declined sharply at extreme pH values in both
ionic-strength buffers. Those results were similar to that of HLZ
(P.0.05, Figure 5). The data of pH stability revealed the purified
rHLZ was quite stable (Figure 6). It also showed that the rHLZ
Figure 2. Purification of rHLZ by cation-exchange chromatography and gel filtration chromatography. (A)PurificationofrHLZbycation-
exchange chromatography. Transgenic milk whey (15 ml) was diluted in 20 mM sodium phosphate buffer, pH 8.5, and applied to the column. (B) The
identification of rHLZ by 15% SDS-PAGE and Coomassie blue staining of the cation-exchange chromatography elution peaks. (C) Western blot
identification of the elution peaks after cation-exchange chromatography. HLZ, commercial HLZ; N, milk from a non-transgenic cow; P1, P2 and P3
represent different elution peaks form cation-exchange chromatography; F represents the flow through. (D) Gel-filtration chromatography of the partly
purified rHLZ from cation-exchange chromatography. The P2 fraction shown in A was loaded on the column after being concentrated with a centrifugal
filter. (E) The identification of rHLZ by SDS-PAGE (15% gel) after Coomassie blue staining of elution peaks. HLZ, commercial HLZ; N, milk from a non-
transgenic cow; M, protein marker; P1, P2 and P3 represent different elution peaks form Gel-filtration chromatography. (F) Western blot identification of
SP Sepharoseelution peaks. HLZ, commercial HLZ; N, milk from a non-transgenic cow; M, protein marker. P1, P2 andP3 represent different elution peaks
form Gel-filtration chromatography. (G) The purified rHLZ protein after a two-step purification process was identified by SDS-PAGE (15% gel) and silver
staining. HLZ, commercial HLZ. P2 represent elution peaks form Gel-filtration chromatography which is labeled in figure part D.
doi:10.1371/journal.pone.0017593.g002
Table 2. Comparison of the protein characteristics of purified
rHLZ and commercial HLZ.
rHLZ from transgenic
cattle Commercial HLZ
N-terminal sequence KVFERCELARTLKRL KVFERCELARTLKRL
Molecular mass 14,679.14 Da 14,674.19 Da
Lytic activity (U/mg) 117,089.369,471.50 114,413.8622,470.78
doi:10.1371/journal.pone.0017593.t002
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2.0 to 11.0 (P.0.05), indicating that the enzymes are resistant to
acid-base environments.
Discussion
To our knowledge, this is the first study that resulted in the
production of a herd of cloned transgenic cattle that expressed
rHLZ in their milk. The transgenic milk allows for the transfer of
the nutritional aspects of HLZ from human milk to bovine milk. It
is fulfilled the conception of humanizing the bovine milk. In
addition, a previous report showed that over-expression of
antimicrobial compounds in livestock milk can improve udder
health and inhibit the microorganisms that cause mastitis [25,30];
therefore, our model can be explored whether the additional
benefits for cattle would exist. Moreover, we have provided a way
to produce HLZ, one that can be expanded on an industrial scale.
The modified bovine milk is a possible substitute for human
milk which has been shown to be able to produce a number of
transgene-expressed proteins [24,31]. In preliminary work, we
have established two different kinds of transgenic mice, pBC-hLY
and pBC-sighLY, as model systems for the expression of rHLZ.
The highest concentration is about three times than that of the
level in human whey. It suggested that the vectors were
successfully constructed to express the rHLZ in mammary gland
[28]. On the basis of those findings, we modified the pBC-sighLY
expression vector to create the pBC2-HLY-NEOR expression
vector to promote the expression of rHLZ in transgenic cattle. In
milk from four naturally lactating transgenic cattle, the average
expression level of rHLZ was lower (13,26 mg/ml) than other
reported recombinant proteins in cattle (lactoferrin) and goats
(lysozyme) [27,32]. Some reasons might cause this difference.
Firstly, more regulatory elements in transgenic vector may lead to
high expression level, for example using bacterial artificial
chromosome (BAC) in other report [32]. Secondly, the different
levels of expression among transgenic cattle may relate to the copy
numbers of the transgene [33]. Thirdly, transgene may integrate
into the chromosome of an inactive transcription region, so a
positional effect could cause the expression low [31,34]. In
addition, many factors of the SCNT procedure, such as the quality
of the donor cells, the nuclear reprogramming, could also lead to
different levels of expression [35–37]. The exact mechanisms
remain to be determined, however.
To extract rHLZ of high purity (.95%), we established a simple
two-step method for the purification of the recombinant protein
from milk. This purification scheme provides a new, cost-effective
method for the extraction of rHLZ from transgenic milk. Affinity
chromatography for the separation of HLZ can yield a high
recovery and concentration [38]; however, the media used in
affinity chromatography are costly, and the coupling procedure is
complex and time consuming. This method therefore has limited
application on an industrial scale. Cation-exchange chromatogra-
phy has advantages over affinity chromatography. It used to be as
a common method for the purification of rHLZ in other
expression systems [29,39]. We selected phosphate buffers for
purification, and we optimized the pH and salt concentration. The
best elution condition was with a buffer of 0.3 M sodium chloride
and 20 mM sodium phosphate at a pH of 8.5. Because bovine
milk contains only 0.1 mg/ml of lysozyme [16], we are not
concerned about the influence of the endogenous lysozyme.
The transgenic technique is associated with the problem of
random integration [31,34]. Incomplete reprogramming of
transgenic animals can result in errors in gene expression [40].
Figure 3. Lytic activity of rHLZ, HLZ, and hen egg white
lysozyme against Micrococcus lysodeikticus. The small circles (7 mm
in diameter) consist of quantitative filter paper with 2 mg of test sample
at 0.2 mg/ml or sterile water (control). The larger circles are the
inhibition zones. A, commercial HLZ; B, purified rHLZ-1, which was not
desalinated; C, hen egg white lysozyme; D, purified rHLZ; E, sterile water
(control).
doi:10.1371/journal.pone.0017593.g003
Table 3. The lytic activity, determined by the turbidimetric
method, against Micrococcus lysodeikticus cells.
Concentration
(mg/ml)
1 Activity (mean ± S.D., U/mg)
Commercial HLZ 0.901 114,413.8622,470.78
rHLZ 0.1966 117,089.369,471.50
rHLZ-1
2 0.1202 79,444.4463,367.88
HLZ
3 0.04832 141,979621,891.54
Hew-LZ
4 86.3764 42,604.2565,657.47
1The concentration of HLZ and rHLZ was quantified by ELISA. The commercial
hew-LZ was quantified by UV specrophotometer.
2rHLZ-1 is purified rHLZ that was not desalinated.
3HLZ is purified lysozyme from human milk that was purified using the same
methodology used to purify rHLZ.
4Hew-LZ is hen egg white lysozyme.
doi:10.1371/journal.pone.0017593.t003
Table 4. Optimal temperature for purified rHLZ and HLZ by
detecting the lysozyme activity.
Commercial HLZ rHLZ
25uC (units/mg) 10,44568,326 120,027610,035
40uC (units/mg) 121,907610,006 137,35863,512
60uC (units/mg) 101,26367,013 110,00767,964
80uC (units/mg) 78,75067,563 86,423612,550
doi:10.1371/journal.pone.0017593.t004
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animals behave normally and do not show any differences from
non-transgenic animals, except for the expression of heterologous
protein [32,41,42]. Our study provided that the gross composition
of milk showed no significant difference between transgenic and
non-transgenic cattle (P.0.05). Though the fatty acid and total
milk solids of one of the transgenic cattle was a little higher than
that of the others, the difference is within the normal range for
Holstein cattle as a whole when examining data from the literature
[42–44]. The pattern of the protein distribution in milk from
transgenic and non-transgenic cattle was similar. This conclusion
was reached from the results of the SDS-PAGE analysis, but the
results will need to be validated by two-dimensional gel
electrophoresis, mass spectrometry, and bioinformatics. In addi-
tion, the fatty acid, amino acid, mineral, and vitamin composition
of the milk produced by transgenic and non-transgenic cattle will
need to be measured and validated in future research. Of cause,
the health and welfare of the transgenic animals should be
considered [45].
We examined the physical and chemical characteristics of the
rHLZ secreted in bovine milk. All of the results indicated that the
purified rHLZ was similar to the natural HLZ. Although there was
a minor difference in molecular mass between rHLZ and HLZ,
post-translational modification did not occur with rHLZ. The
minimum mass increase of protein peptide levels after different
types of post-translational modification is due to methylation with
an increase of 14 Da [46]. Peptide molecular fingerprinting maps
of purified rHLZ were similar to those of HLZ, which
demonstrates that rHLZ has the same primary structure as
HLZ. Furthermore, the sequence-determined N terminus of the
purified rHLZ in this study matched that of HLZ from another
study [47]. This result indicates that the signal peptide of bovine b-
casein connecting to rHLZ was cut correctly in the bovine
mammary epithelial cells.
A well-known property of lysozyme is its lytic activity against
Gram-positive bacteria. rHLZ displayed a level of lytic activity
that was similar to that of HLZ (P.0.05) and three times higher
than that of hen egg white lysozyme.
The optimal temperature and thermostability of the transgenic
milk were assayed because post-processing stability and storage of
transgenic milk are important considerations for commercial
production. The U.S. Food and Drug Administration requires that
Grade A pasteurized milk undergoes a minimum heating at 63uC
for 30 min or 72uC for 15 s [48]. For transgenic milk to be
processed into milk powder, much higher temperatures (70uC–
100uC) must be tolerated during the spray-drying process. In our
study, rHLZ purified from transgenic milk had the same optimal
temperature and was equally thermostable as HLZ (P.0.05). We
conclude that post-processing procedures will have only minor
effects on rHLZ activity.
The optimal pH of the purified rHLZ and HLZ varied with salt
concentration in this study. A similar phenomenon was observed
with hen egg white lysozyme [49] and oyster lysozyme [50]. We
also found that the lytic activity of the lysozymes varied with pH.
This might be because the different solutions change the positive
charge at the surface of the lysozyme and the negative charge of
the cell wall, which reacts with lysozyme [51,52]. The pH stability
assay revealed that rHLZ and HLZ were both stable at an acid pH
and an alkaline pH (pH 2–11). These properties are similar to
those reported by Chandan et al. [16]. The pH of cow milk is
around 6.8 [53], which is optimal for the lytic activity of rHLZ.
Earlier reports suggest that rHLZ may extend the shelf-life of goat
milk [25]. We infer that rHLZ will prolong the shelf-life of
transgenic bovine milk, and we are currently studying this
possibility.
In conclusion, we successfully produced healthy transgenic
cattle that expressed rHLZ. This approach could provide an
inexpensive and industrial-scale method for the purification of
rHLZ. In addition, we have shown that the enzymatic properties
and physicochemical characteristics of rHLZ were identical to
those of HLZ. Transgenic cow milk will likely be beneficial to the
Figure 4. Thermostability of purified rHLZ and HLZ at 606C,
806C, and 1006C. The lysozyme activity assay was carried out using
the turbidimetric method with a spectrophotometer at A450. Lytic
activity was measured against Micrococcus lysodeikticus in 66 mM
potassium phosphate buffer, pH 6.24, at 25uC after incubation for
different times at 60uC (A), 80uC (B), and 100uC (C). Lysozyme activity
measured at 25uC represented 100% activity. rHLZ, purified rHLZ; HLZ,
commercial HLZ. The experiment for each group was repeated at least
three times, and the results represent mean 6 S.D.
doi:10.1371/journal.pone.0017593.g004
Recombinant Human Lysozyme
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using HLZ-transgenic goat milk [25,54,55].
Materials and Methods
Production of transgenic cattle
The rHLZ expression vector pBC2-HLY-NEOR (Figure 1A)
was derived from the pBC-sighLY expression vector that was
expressed previously in transgenic mice [28]. A 31-bp sequence
from bp 6,407 to bp 6,438 (GAATTCATTTCCTAATCATG-
CAGATTTCTAG) of the goat ß-casein promoter was removed
from the pBC-sighLY expression vector. A selection marker, Neor
(neomycin resistance gene), was added to the vector. The new
expression vector therefore contained: the HLZ coding region; the
bovine ß-casein signal peptide DNA sequece; the goat ß-casein
promoter without the 31-bp fragment; the 39 genomic sequence,
exon 1, intron 1, part of exon 2 (before the initial codon), exon 7,
intron 7, exon 8, intron 8, and exon 9 of goat ß-casein; two copies
of the chicken ß-globin insulator; and the selection marker, Neor.
The restriction enzyme SalI was used to digest a 28-kb fragment
containing HLZ from the pBC2-HLY-NEOR expression vector
(Figure 1A). The fragment was then transfected into embryonic
fibroblasts, oviduct epithelial cells, and genital ridge cells using
electrotransformation with a DC pulse of 1.2 kV/cm for 1 ms.
After selection with 800 mg/ml GeneticinH (G418; Life Technol-
ogies, Carlsbad, CA), several positive colonies were isolated.
SCNT was then conducting using the methods of Gong et al. [56].
A total of 312 embryos were transferred into recipient Chinese
Luxi yellow cattle. All animal procedures were approved by the
Institutional Animal Care and Use Committee at the China
Agricultural University(ID: SKLAB-B-2010-003).
Detection of rHLZ
Polymerase chain reaction (PCR) analysis. PCR analysis
of DNA from the ears of transgenic and non-transgenic cattle was
performed with a pairs of primers. The primers, HLY3 and PCR
product information are provided in Table 5.
Southern blot analysis. Genomic DNA (20 mg) from ear
biopsies of transgenic and non-transgenic cattle was digested using
EcoRI and separated on a 1% agarose gel before transfer to a
Hybond+ membrane (Amersham Pharmacia Biotech, Piscataway,
NJ). Southern blot analysis was performed using a 565-bp, HLZ-
specific hybridization probe labeled with digoxigenin (DIG) using
Figure 5. The optimal pH for the lytic activity of purified rHLZ and commercial HLZ in buffers with different salt concentration. The
lysozyme activity was measured using the turbidimetric method with a spectrophotometer at A450. The lytic activity was measured against
Micrococcus lysodeikticus in sodium acetate buffers of pH 2–5, potassium dihydrogen phosphate buffers of pH 6–8, and carbonate bicarbonate
buffers of pH 9–11. Lytic activity measured in potassium dihydrogen phosphate buffer, pH 6, represented 100% activity for salt concentration at
0.1 M. Lytic activity measured in potassium dihydrogen phosphate buffer, pH 7, represented 100% activity for salt concentration at 0.05 M. (A) The
optimal pH for commercial HLZ at salt concentration of 0.1 M and 0.05 M. (B) The optimal pH for purified rHLZ at salt concentration of 0.1 M and
0.05 M. The experiment for each group was repeated at least three times, and the results represent mean 6 S.D.
doi:10.1371/journal.pone.0017593.g005
Figure 6. pH stability of purified rHLZ and commercial HLZ.
Commercial HLZ and purified rHLZ were incubated in sodium acetate
buffers of pH 2–5, potassium dihydrogen phosphate buffers of pH 6–8,
and carbonate bicarbonate buffers of pH 9–11 for 20 min. The
lysozyme activity was then assayed, using the turbidimetric method,
against Micrococcus lysodeikticus in potassium dihydrogen phosphate
buffer, pH 7, at salt concentration of 0.05 M. The lytic activity incubated
in potassium dihydrogen phosphate buffer, pH 7, at salt concentration
of 0.05 M represented 100% activity. HLZ represents commercial HLZ;
rHLZ represents purified rHLZ. The experiment for each group was
repeated at least three times, and the results represent mean 6 S.D.
doi:10.1371/journal.pone.0017593.g006
Table 5. Primers for PCR analysis.
Primer
name Primer sequence (59–39)
The target
amplification
HLY3-F CAGCACTTTGGGAGACCGA 1,600 bp
HLY3-R CATCTTCAGTATTTTGCCCTC
GAPDH-F CGACTTCAACAGCGACACTCAC 121 bp
GAPDH-R CACCCTGTTGCTGTAGCCAAA
RT-F ATCAGCCTAGCAAACTGGAT 322 bp
RT-R CTCCACAACCTTGAACATAC
doi:10.1371/journal.pone.0017593.t005
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CA). The positive hybridization signal was a ,3-kb fragment.
Genomic DNA from non-transgenic cattle was used as the
negative control. The pBC2-HLY-NEOR plasmid DNA was
used as the positive control. Copy numbers of the transgene were
quantified using Quantity One software (Bio-Rad, Hercules, CA).
Reverse transcription-PCR (RT-PCR) analysis. RNA was
extracted from the mammary epithelial cells of transgenic and
non-transgenic cattle for use in RT-PCR. The extraction
procedure involved centrifuging 100-ml samples of milk at
4,0006 g for 10 min, carefully removing the milk fat and
supernatant on the top layer of each tube, resuspending the
sediment in 20 ml PBS with 0.5 mM EDTA, and then
centrifuging the suspension at 4,0006 g for 10 min. Each pellet
was used immediately for RNA extraction with the RNeasyH Mini
kit (QIAGEN, Hilden, Germany). The RNA samples were eluted
with RNase-free water and stored at 280uC.
The first strand of cDNA was synthesized using M-MLV reverse
transcriptase according to the manufacturer’s instructions (Pro-
mega, Madison, WI) and was subsequently used as the template
for PCR. RT-PCR primers were designed on the basis of the HLZ
coding sequences, and the upstream primer was designed across
one intron. The primers (GAPDH and RT) are shown in Table 5.
The negative control was performed using RNA pool from all
samples as PCR template.
Western blot analysis. Transgenic and non-transgenic cattle
of 6–8 months of age were induced with agent of induction
(National Caotan Pharmacy Company, Xi’an China) to produce
milk. Milk was collected three times per week for 1 month. Skim
milk which was produced by centrifuging at 4,0006g for 10 min
was separated by 15% SDS-PAGE and electro-transferred onto
nitrocellulose membranes (Amersham Pharmacia Biotech) for
western blot analysis. Rabbit polyclonal antibody against HLZ
(US Biological, Swampscott, MA) and horseradish peroxidase–
conjugated goat anti–rabbit IgG (Biodesign, Saco, ME) were used
to detect rHLZ. The positive control used in western blot analysis
was the commercial HLZ (Sigma, St. Louis, MO). The negative
control was non-transgenic milk.
Quantification of rHLZ by radioimmunoassay. The
amount of rHLZ in the milk of naturally lactating transgenic cattle
over the first month of lactation was carried out at the Institute of
Atomic Energy Utilization (Beijing, China) for radioimmunoassay
(RIA). The experiment for each sample was repeated at least three
times, and the results represent mean 6 S.D.
Analysis of milk components
The transgenic cattle 0503, 0504, 1241, and 1242 were selected
for analysis of the gross composition of their milk. The non-
transgenic cattle 2006, 1019, 020, and 1009 were used as controls.
The breeding conditions were identical for the two groups. Milk
samples were collected once a month for a period of 6 months
after parturition. The percentage (w/vol) of fat, protein, lactose,
and solid were determined using a MilkoScan 4000 (Foss,
Hillerod, Denmark).
Purification of rHLZ from transgenic milk
Sample preparation. Milk was defatted by centrifugation at
2,6006 g at 4uC for 10 min. The whey from each sample was
ultracentrifuged at 100,0006g at 20uC for 1 h, and it was diluted
with 100 mM sodium phosphate, pH 8.5, to a final concentration
of 20 mM. The sample solution was filtered with a 0.22-mm filter
before use.
Purification of rHLZ. A two-step purification procedure was
used to isolate rHLZ using an A ¨KTA purifier 10 system
(Amersham Bioscience, Piscataway, NJ). In the first step, a 15-
ml sample was loaded onto a HiLoad 16/10 SP Sepharose HP
column (GE Healthcare, Uppsala, Sweden). After equilibration
with 20 mM sodium phosphate, pH 8.5, bound proteins were
eluted with a linear gradient of 0–0.4 M NaCl in 20 mM sodium
phosphate buffer, pH 8.5. In the second step, fractions containing
rHLZ were concentrated using a 3-kDa-cutoff ultracentrifuge tube
(Utra-15; Millipore Amicon, Bedford, MA) and further purified by
gel filtration using a HiLoad 16/60 Superdex 75 prep-grade
column (GE Healthcare) in 20 mM sodium phosphate buffer with
0.15 M NaCl, pH 7.2. The rHLZ-containing fractions were
concentrated and desalted by ultracentrifugation using a 3-kDa-
cutoff ultracentrifuge tube (Millipore Amicon Utra-15). The
collecting solution was then freeze-dried using Freezone 6
(Labconco, Kansas City, MO). The rHLZ fraction was
identified by SDS-PAGE and western blotting. An ELISA kit
(BTI, Stoughton, MA) was used to quantify the purified rHLZ, in
accordance with the manufacturer’s instructions.
Characterization of rHLZ
N-terminal amino acid sequencing of purified rHLZ and
HLZ. Purified rHLZ was sent to Shanghai GeneCore
Biotechnologies Co. Ltd. (Shanghai, China) for N-terminal
amino acid sequence analysis using automatic Edman
degradation. Sequence similarity between the N-terminal amino
acid sequence of rHLZ and other proteins was analyzed using the
BLAST program and the GenBank databases of the National
Center for Biotechnology Information.
MALDI-TOF-MS analysis of molecular weight of purified
rHLZ and HLZ. High-purity rHLZ and HLZ (Sigma-Aldrich)
were assayed by MALDI-TOF-MS (Bruker Daltonics, Billerica,
MA) using a-cyano-4-hydroxycinnamic acid as a matrix at the
linear pattern [57].
Peptide mass fingerprinting of purified rHLZ and
HLZ. After separation by SDS-PAGE, the protein band of
each of purified rHLZ and standard HLZ (Sigma, St. Louis, MO)
was excised and destained using 50% acetonitrile and 50 mM
NH4HCO3. The protein was then digested using sequence-grade
trypsin (Sigma, St. Louis, MO) for 16 h at 37uC. The supernatant
was collected into a clean tube and extracted two times using 0.1%
trifluoroacetic acid at 37uC, and the extraction solutions and
supernatants were dried in a speed-vac (Eppendorf) to a 5 ml final
volume. Sample (1 ml) and 0.5 ml of matrix solution, purified a-
cyano-4-hydroxycinnamic acid (Sigma, St. Louis, MO) were
added onto the MALDI plate, which was then dried at room
temperature. Finally, the samples were analyzed using Autoflex II
(Bruker Daltonics, Billerica, MA) in the reflection mode. Peptide
mass fingerprinting was performed using MASCOT database.
The obtained mass spectra were downloaded to a database for
analysis.
Lysozyme activity assay by the turbidimetric rate
determination method and the agar disc diffusion
method. The turbidimetric method was conducted according
to the lytic assay described by Shugar [58]. Briefly, M. lysodeikticus
(China General Microbiological Culture Collection Center,
Beijing) was used as the substrate, and 2.5 ml of substrate
suspension (A600<0.7–0.8) was prepared at 25uC with in 66 mM
potassium phosphate buffer, pH 6.24. The reaction was initiated
immediately after 100 ml of sample (test group) or ddH2O (blank
group) was added to the substrate solution. Values were recorded
at A450 every 15 s over a 3-min period. The DA450 per minute was
used as the maximum linear rate for both the test and blank
groups. One unit of lysozyme produces a DA450 of 0.001 per
minute. Protein concentrations were calculated as: U/mg
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were measured in triplicate.
The disc diffusion method was performed with nutrient broth
agar (Sigma, St. Louis, MO). Micrococcus lysodeikticus (100 ml) at
mid-log phase (A600<0.6–0.7) was mixed with 20 ml solid culture
medium containing 1.5% agar. Each sample (2 mg) was placed on
a sterile, quantitative filter paper disc (7 mm in diameter) on a
plate, which was incubated for 24 h at 28uC. The results were
assessed by inhibition zones around disc paper. Sterile water was
placed on the filter paper disc as a negative control. The
experiment was repeated three times.
Optimal temperature assay. Quantified and purified
rHLZ and HLZ (Sigma, St. Louis, MO) were diluted to a 100-
ml volume using 66 mM potassium phosphate buffer, pH 6.24.
The collected M. lysodeikticus cells were resuspended in the same
buffer at mid-log phase (A600<0.6–0.8). The samples and substrate
solution were incubated at 25uC, 40uC, 60uC, or 80uC for
approximately 5 min. The lysozyme activity of the samples was
then quickly measured by the turbidimetric method described
above, using triplicate samples.
Thermostability assay. The thermostability of the
quantified and purified rHLZ and HLZ (Sigma, St. Louis, MO)
was tested at 60uC, 80uC, and 100uC. Samples were diluted to
100 ml using 66 mM potassium phosphate buffer, pH 6.24, and
incubated at the operating temperature. At each temperature, the
thermostability of lysozyme was measured at 0 min and after 1, 2,
4, 7, 10, 15, 25, 35, and 45 min of incubation. The incubated
samples were quickly mixed with the bacterial suspension, and the
turbidimetric method described above was used to measure the
lysozyme activity in triplicate samples.
pH and salt concentration optima assay. The lytic activity
of purified rHLZ and HLZ (Sigma, St. Louis, MO) against M.
lysodeikticus was measured at 10 different buffers of varying pH
(pH 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, and 11.0) and two
salt concentration buffers (0.1 M and 0.05 M). A sodium acetate
buffer was used at pH 2.0–5.0, a potassium dihydrogen phosphate
buffer was used at pH 6.0–8.0, and a carbonate bicarbonate buffer
was prepared at pH 9.0–11.0. We prepared a total of 20 buffer
solutions, and these were used to dilute the M. lysodeikticus cells and
samples. The solutions were pre-incubated at 25uC for 10 min
before measuring the lysozyme activity by the turbidimetric
method described above, using triplicate samples.
pH stability assay. For the pH stability test, the samples
were incubated with the different buffers mentioned above for
20 min at 25uC. The lysozyme activity was assayed by using M.
lysodeikticus in a potassium dihydrogen phosphate buffer, pH 7.0 of
0.05 M, and the turbidimetric method described above, using
triplicate samples.
Statistical analysis
Data for milk components, temperature treatment and pH
treatment assay were analyzed by T test using SPSS 13.0, to detect
difference between the test group and control group. All values are
reported as the mean 6 SD.
Supporting Information
Figure S1 The expression level of rHLZ in the milk of
transgenic cloned cattle 1242 at the first month after
lactation. The concentration of rHLZ was determined by RIA.
(TIF)
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